Fundraising Fox

Nemus Bioscience

NASDAQ: SKYE

Costa Mesa, US · Founded 2011 · Nevada corporation

Biotech

Founders & leadership

EM
Elizabeth M. BereczExecutive
JB
John B. HollisterExecutive
BS
Brian S. MurphyExecutive
CN
Cosmas N. LykosNamed on SEC filing

Board

GW
Gerald W. McLaughlinBoard director

Reported raises · per SEC filings

Form D private placements

$168.4M disclosed across 11 of 12 rounds · 2014–2024

▶$40MraisedMar 2024 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Margaret DalesandroDirector
  • Punit DhillonExecutive Officer, Director
  • Kaitlyn ArsenaultExecutive Officer
  • Annalisa JenkinsDirector
  • Praveen TyleDirector
  • Deborah CharychDirector
  • Paul GraysonDirector
  • Andrew SchwabDirector
  • Keith WardDirector
Offering amount
$40M
Amount sold
$40M
Sales commissions
$2.4M
Placement agents
Oppenheimer & Co. Inc., Piper Sandler & Co
First sale
Mar 2024
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedFeb 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith WardDirector
  • Margaret DalesandroDirector
  • Kaitlyn ArsenaultExecutive Officer
  • Paul GraysonDirector
  • Praveen TyleDirector
  • Punit DhillonExecutive Officer, Director
  • Deborah CharychDirector
  • Andrew SchwabDirector
Offering amount
$50M
Amount sold
$50M
Sales commissions
$3.5M
Placement agents
Oppenheimer & Co. Inc., Piper Sandler & Co
First sale
Jan 2024
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$62.3MraisedAug 2023 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Praveen TyleDirector
  • Kaitlyn ArsenaultExecutive Officer
  • Deborah CharychDirector
  • Keith WardDirector
  • Punit DhillonExecutive Officer, Director
  • Margaret DalesandroDirector
  • Andrew SchwabDirector
  • Paul GraysonDirector
Offering amount
$62.3M
Amount sold
$62.3M
First sale
Aug 2023
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2018 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas A. CesarioExecutive Officer
  • Punit DhillonDirector
  • Avtar DhillonDirector
  • Brian S. MurphyExecutive Officer, Director
  • James L. HeppellDirector
Offering amount
$32.5M
Amount sold
$2M
First sale
Nov 2018
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedFeb 2018 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James L. HeppellDirector
  • Brian S. MurphyExecutive Officer, Director
  • Elizabeth M. BereczExecutive Officer
  • Punit DhillonDirector
Offering amount
$8.6M
Amount sold
$4.2M
First sale
Jan 2018
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2017 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas S. IngramDirector
  • Gerald W. McLaughlinDirector
  • Brian S. MurphyExecutive Officer, Director
  • Cosmas N. LykosExecutive Officer, Director
  • Elizabeth M. BereczExecutive Officer
  • Thomas A. GeorgeDirector
Offering amount
$2M
Amount sold
$2M
First sale
Nov 2017
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedJan 2017 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian S. MurphyExecutive Officer
  • Yosbani MendezPromoter
  • Thomas A. GeorgeDirector
  • Douglas S. IngramDirector
  • Cosmas N. LykosExecutive Officer, Director
  • Francicso MendezPromoter
  • Gerald W. McLaughlinDirector
  • Elizabeth M. BereczExecutive Officer
Offering amount
$1.5M
Amount sold
$1.2M
Placement agents
Roth Capital Partners, LLC
First sale
Jan 2017
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedNov 2016 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Yosbani MendezPromoter
  • Douglas S. IngramExecutive Officer, Director
  • Cosmas N. LykosExecutive Officer, Director
  • Brian S. MurphyExecutive Officer
  • Elizabeth M. BereczExecutive Officer
  • Francicso MendezPromoter
  • Gerald W. McLaughlinDirector
  • Thomas A. GeorgeDirector
Offering amount
$500K
Amount sold
$500K
Sales commissions
$50K
Placement agents
Roth Capital Partners, LLC
First sale
Oct 2016
Incorporated
Corporation, Nevada, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Nemus Bioscience: A Promising Medical Marijuana Play (NASDAQ:GWPH) | Seeking Alphaseekingalpha.com · Oct 2018Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeuticsglobenewswire.com · Jan 2018

Frequently asked questions

How much funding has Nemus Bioscience raised?
Nemus Bioscience has disclosed $168.4M raised across 11 of its 12 known rounds.
Where is Nemus Bioscience headquartered?
Nemus Bioscience is headquartered in Costa Mesa, US.